MedTrace Logo

Omega-3 Supplementation in Cervix Cancer Patients Undergoing Chemoradiotherapy

NCT02779868 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-07-25

No results posted yet for this study

Summary

Cancer cachexia is a complex metabolic process affecting up to 80% of patients suffering from an advanced-stage cancer. Moreover, 20 to 40% of all cancer deaths are caused directly by cachexia. Recently, omega-3 fatty acids have gained interest for their beneficial effects in cancer cachexia. Moreover, nutritional supplementation enriched with omega-3 could potentially maintain body weight in cancer patients undergoing intensive treatment.

The investigators aims in this study is to evaluate the effect of omega-3 supplementation on body composition, functional capacity, inflammatory profile and quality of life in cervix cancer patients undergoing chemoradiotherapy.

Conditions

Interventions

DIETARY_SUPPLEMENT

Omega-3

patients included in this group will take 2g (4 capsules) per day of eicosapentaenoic acid.

DIETARY_SUPPLEMENT

Olive oil

patients included in this group will take 4 capsules per day of olive oil.

Sponsors & Collaborators

  • Brazilian National Cancer Institute

    lead OTHER_GOV

Principal Investigators

  • Mariah A Aredes, Ms · Brazilian National Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
59 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02779868 on ClinicalTrials.gov